This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

CAS Medical Systems Names Dr. John Gamelin As Vice President Of Research & Development

BRANFORD, Conn., Dec. 17, 2012 (GLOBE NEWSWIRE) -- CAS Medical Systems, Inc. (Nasdaq:CASM) (CASMED), a leader in medical devices for non-invasive patient monitoring, announces the promotion of John Gamelin, Ph.D., to Vice President, Research & Development. Dr. Gamelin has been with CASMED since 2009 and most recently served as Director of Research & Development.

"John has made a tremendous contribution to the revitalization of CASMED and is responsible for driving the three major development programs that will deliver new products in each of our core markets within the next year," said Tom Patton, Chief Executive Officer of CASMED. "In addition to John's management skills, as a small company we benefit greatly from his entrepreneurial talents and his broad scientific and clinical competencies. We are pleased to make this well-deserved promotion and elevate John to senior management of the Company."

Dr. Gamelin has more than 20 years of experience inventing and developing optical, acoustic, and electronic instrumentation, from research concept to commercial production. Prior to joining CASMED, he served as Research Assistant Professor at the University of Connecticut in its Biomedical Engineering program, where he conducted research on novel optical, ultrasound, and radiation imaging modalities for cancer detection and diagnostics. Previously, as a co-founder and Vice President of Engineering for Tellium, an optical switching company, John was a key player in driving that company from start-up to over $100 million in revenues in just four years. At Tellium he ultimately led a development organization of over 200 professionals through major releases of various products, including the largest capacity optical switch available commercially. He began his career as a Senior Scientist at Bellcore, the research and engineering organization for the Regional Bell Operating Companies.

Dr. Gamelin holds four U.S. patents in optical cross-connects and switching technology and several patent applications in biomedical imaging and medical instrumentation. He is the author or co-author of more than 50 publications on topics that include biomedical imaging and laser transmitters. He received his Ph.D. in electrical engineering from the University of California, Berkeley, and his B.S. in electrical engineering from the University of Florida, Gainesville, graduating with distinction as Valedictorian.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs